Change of Nerve Conduction Properties in IVIg Dependent Neuropathies

University of Cologne50 enrolled

Overview

IVIg exert a variety of different immunomodulatory effects and several mechanism of action have been proposed for IVIg. In this study the role of IVIg on short term nerve conduction in patients with immune-mediated neuropathies will be explored.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Guillain-Barre Syndrome CIDP Multifocal Motor Neuropathy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * immune neuropathy * age above 18 y * IVIg treatment exclusion: * no IVIg treatment

Locations (1)

University of Cologne

Cologne, Germany

Outcomes

Primary Outcomes

Clinical Improvement

Time frame: 6 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.